Pudendal Nerve Clinical Trial
Official title:
A Prospective Randomized Clinical Trial Using Amniotic Membrane in Robotic Assisted Laparoscopic Prostatectomy (RALP)- Effect on Nerve Protection.
Verified date | March 2015 |
Source | MiMedx Group, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The purpose of this study is to determine whether the AmnioFix dehydrated human amniotic membrane is effective in protecting nerves in men receiving robotic assisted laparoscopic prostatectomies.
Status | Completed |
Enrollment | 34 |
Est. completion date | June 2014 |
Est. primary completion date | June 2014 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 45 Years to 70 Years |
Eligibility |
Inclusion Criteria: 1. Ages 45-70 2. Clinically localized prostate cancer with Gleason score 6 or 7 3. SHIM Score greater than or equal to 16 in the absence of medication 4. Feasibility to perform unilateral or bilateral nerve sparing RALP Exclusion Criteria: 1. Clinically locally advanced cancer and/or with Gleason score 8 or 9. 2. Difficulty performing nerve sparing RALP. 3. Prior surgery at the site. 4. Site exhibits clinical signs and symptoms of infection. 5. SHIM score at screening <16. 6. Current use of anticoagulant medication including Coumadin, Plavix, etc. 7. Has had "salvage prostatectomy" - patients who failed prior therapies including external radiation therapy, cryotherapy, etc. 8. Has prior radiation therapy treatment at the site. 9. Prior hormonal therapy such as Lupron or oral anti-androgens. 10. Non-mobile, i.e. not ambulatory or bed ridden. 11. The presence of comorbidities that can be confused with or can exacerbate the condition including: 1. diabetes 2. advanced atherosclerotic vascular disease 12. Patients with a history of more than two weeks treatment with immuno-suppressants (including systemic corticosteroids), cytotoxic chemotherapy within one month prior to initial screening, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study. 13. Patients on any investigational drug(s) or therapeutic device(s) within 30 days preceding screening. 14. Unable to comply with penile rehabilitation. 15. Known history of having Acquired Immunodeficiency Syndrome (AIDS) or HIV. 16. Patients who are unable to understand the aims and objectives of the trial. 17. Presence of any condition(s) which seriously compromises the subject's ability to complete this study, or has a known history of poor adherence with medical treatment. 18. Currently taking medications which could affect graft incorporation (supervising physician's discretion). 19. Allergic to gentamicin and/or streptomycin. 20. Damage to neurovascular bundles during surgery. |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Jackson South Urology Center of Excellence | Miami | Florida |
Lead Sponsor | Collaborator |
---|---|
MiMedx Group, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The proportion of patients achieving return to baseline Sexual Health Inventory for Men (SHIM) score in the AmnioFix group versus the Control group. | 4 weeks | No | |
Secondary | Time to return of erectile function. | Up to 6 months | No | |
Secondary | Pain scores. | 10 days, 4 weeks, 3 months, and 6 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03973983 -
Comparison of Ultrasound-guided Transgluteal and Finger-guided Transvaginal Pudendal Nerve Block Techniques
|
N/A | |
Active, not recruiting |
NCT06397625 -
Treatment With Peripheral Nerve Stimulation of the Pudendal Nerve in Patients With Erectile Dysfunction
|
N/A | |
Recruiting |
NCT04288349 -
IntraopeRativE Use of periNeal Block for Hemorrhoidectomy
|
N/A |